Corporate Ads

Major Solar Infrastructure Surveying Awards, a Multi-Billion-Dollar Grid Upgrade, 31 DaaS Acquisitions and Targeted 40%–60% Profit Margins Highlight a Company Building Serious Commercial Momentum

Genprex, Inc. (N A S D A Q: GNPX) Provides New Clinical Patient Analysis Uncovers Promising TUSC2-Associated Biological Activity Involving Mitochondrial Function, Cellular Repair, Autophagy and Protein Quality Control.

Strategic Roche Diagnostics Partnership, New Biomarker Findings and Expanding Clinical Research Could Help Transform Patient Selection for Non-Small Cell Lung Cancer Treatment, While Genprex, Inc.

NRx Pharmaceuticals, Inc. (N A S D A Q: NRXP) $NRXP Also Received an $11 Million Dollar Award for Robotic Magnetic Stimulation with Pharma Treatment for Resistant Depression

31 DaaS Acquisitions, 425% First-Half Revenue Growth, Expanding International Operations and a Growing AI Technology Portfolio Put ZenaTech, Inc. (N A S D A Q: ZENA) Multi-Industry Vision in the Spotlight

A Landmark October 30th FDA Approval, Commercial Manufacturing Readiness, Two-Year Stability Results, and an $11.25 Million DARPA Research Contract Put NRx Pharmaceuticals, Inc. (N A S D A Q: NRXP) at an Important Turning Point in Its Growth

With Preliminary Q3 Revenue Estimated at Up to C$14.8 Million, 425% First-Half Growth and an Expanding AI Drone Ecosystem, ZenaTech $ZENA Is Building a Bigger Opportunity for Investors

Roche Diagnostics $RHHBY Collaboration, Promising REQORSA® Biomarker Research, and Expanding Gene Therapy Programs Put Genprex $GNPX in the Spotlight

$SNNC acquires Majority Stake in New Joint Venture With Doc-Rx Opens the Door to Telehealth, U.S.-Made Peptides and an Ambitious Wellness Clinic Expansion Strategy

$CYCU Boasts a 30 Million Annual Run Rate After Signing Largest Contract Ever, Valued Over $54 Million